NCT02343718 is a Phase 1 clinical trial of Vinblastine in Recurrent Lymphoma, sponsored by Canadian Cancer Trials Group.

Who is sponsoring NCT02343718?

NCT02343718 is sponsored by Canadian Cancer Trials Group.

What drugs are being tested in NCT02343718?

Interventions in NCT02343718: Vinblastine, Temsirolimus.

What condition does NCT02343718 study?

NCT02343718 studies Recurrent Lymphoma, Refractory Lymphoma, Solid Tumours, Central Nervous System.

Is NCT02343718 still recruiting?

NCT02343718 is currently completed. Last updated 4 August 2023.

Last reviewed 2023-08-04 · How we verify

NCT02343718

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours

Completed Phase 1 Last updated 4 August 2023

What this trial tests

Phase 1 trial testing Vinblastine in Recurrent Lymphoma in 7 participants. Completed in 16 January 2019.

Timeline

24 June 2015

Primary endpoint
28 September 2017

16 January 2019

Quick facts

Lead sponsor	Canadian Cancer Trials Group
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	7
Start date	24 June 2015
Primary completion	28 September 2017
Estimated completion	16 January 2019
Sites	6 locations across Canada

Drugs / interventions tested

Vinblastine — full drug profile →
Temsirolimus (temsirolimus) — full drug profile →

Conditions studied

Recurrent Lymphoma — all drugs for Recurrent Lymphoma →
Refractory Lymphoma — all drugs for Refractory Lymphoma →
Solid Tumours — all drugs for Solid Tumours →
Central Nervous System — all drugs for Central Nervous System →

Sponsor

Canadian Cancer Trials Group — full company profile →

Who can join

Adults 1 to 18, any sex, with Recurrent Lymphoma or Refractory Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine the best dose of vinblastine that can be given with a new drug, temsirolimus.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Novel Therapies for Relapsed and Refractory Neuroblastoma.
Zage PE. · · 2018 · cited 39× · PMID 30384486 · DOI 10.3390/children5110148
Targeting mTOR for the treatment of B cell malignancies.
Lee JS, Vo TT, Fruman DA. · · 2016 · cited 30× · PMID 26805380 · DOI 10.1111/bcp.12888

Verify or expand the search:

Other trials of Vinblastine

Trials testing the same drug.

NCT06960577 — Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cance · Phase 3 · recruiting
NCT06745076 — Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Ho · Phase 2 · recruiting
NCT06831370 — A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India · Phase 4 · recruiting
NCT06381570 — Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade Glioma · EARLY_PHASE1 · recruiting
NCT06204614 — Drug Screening Using IMD in Bladder Cancer · EARLY_PHASE1 · unknown

Other recruiting trials for Recurrent Lymphoma

Currently open trials in the same condition.

NCT05663502 — Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers · recruiting
NCT04870944 — CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma · Phase 1, PHASE2 · recruiting
NCT05071209 — Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors · Phase 1, PHASE2 · active not recruiting
NCT04090619 — Frequency of Cachexia in Ambulatory Cancer Patients and Psychological Burden in Patients and Their Primary Caregivers · active not recruiting
NCT04320888 — Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene A · Phase 2 · active not recruiting

Other Canadian Cancer Trials Group trials

Trials by the same sponsor.

NCT07390435 — Feasibility and Acceptability of Collecting Sociodemographic Data in CCTG Trials · not yet recruiting
NCT07297667 — GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours · Phase 1 · not yet recruiting
NCT06630273 — Canadian Initiative to Measure, Predict and Assess Cancer Treatment Outcomes in Patients Treated With Immuno-Oncotherape · not yet recruiting
NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
NCT07341191 — Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02343718 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Canadian Cancer Trials Group
Last refreshed: 4 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02343718.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing